Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Chicago
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed diagnosis of cancer (including epithelial carcinoma, sarcoma, and melanoma)
Age 18 years and older
Life expectancy of \> 3 months
Patients with AJCC (6th edition, 2002) stage IV cancer with distant metastases and without pleural or pericardial effusion at diagnosis and before start of study
Patients with 1-5 sites of maximum tumor dimension (for each individual site) of ≤ 10 cm or \< 500 cc volume and amenable to radiation therapy as seen on standard imaging
Unidimensionally measurable disease (based on RECIST) is desirable but not strictly required
Brain metastases must have been treated prior to enrollment on study, preferably with stereotactic radiosurgery
ECOG performance status ≤ 2 or Karnofsky Performance Status ≥ 60%
No prior radiation therapy to currently involved tumor sites
Room air saturation \> 90%
Hemoglobin \> 9.0 g/dl
ANC \>=1,500/microliter
Platelets \>=100,000/microliter
Total bilirubin within institutional limits
Albumin \> 2.9 g/dl
Alkaline phosphatase \< 2.5x upper limit of normal
AST and ALT \< 2.5 x upper limit of normal
Ability to understand and willingness to sign a written informed consent document
You may not be if
Uncontrolled intercurrent illness
Patients with clinically significant pulmonary dysfunction, cardiomyopathy, or any history of clinically significant CHF are excluded. Exclusion of patients with active coronary heart disease will be at the discretion of the attending physician
Patients with significant atelectasis such that CT definition of gross tumor volume is difficult to determine
Pregnancy or breast feeding
Patients must have no uncontrolled active infection other than that not curable with treatment of their cancer.
Patients may not be receiving any other investigational drugs during RT
Clareo Health | Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer
